Western Wealth Management LLC Boosts Stake in AbbVie Inc. $ABBV

Western Wealth Management LLC boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 1.2% in the 2nd quarter, Holdings Channel reports. The fund owned 21,744 shares of the company’s stock after acquiring an additional 252 shares during the quarter. Western Wealth Management LLC’s holdings in AbbVie were worth $4,036,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in ABBV. Brighton Jones LLC boosted its stake in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC raised its holdings in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares during the period. Jackson Creek Investment Advisors LLC acquired a new position in AbbVie during the 1st quarter worth about $688,000. Formidable Asset Management LLC grew its position in AbbVie by 1.1% in the 1st quarter. Formidable Asset Management LLC now owns 10,590 shares of the company’s stock valued at $2,219,000 after acquiring an additional 119 shares in the last quarter. Finally, AMG National Trust Bank lifted its holdings in AbbVie by 3.2% during the 1st quarter. AMG National Trust Bank now owns 22,776 shares of the company’s stock worth $4,772,000 after buying an additional 711 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Performance

Shares of ABBV stock opened at $232.43 on Friday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The firm has a market capitalization of $410.79 billion, a price-to-earnings ratio of 110.68, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a one year low of $163.81 and a one year high of $244.81. The company has a 50 day moving average price of $224.89 and a 200 day moving average price of $203.98.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the previous year, the company earned $3.00 EPS. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is presently 524.24%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. BMO Capital Markets boosted their target price on shares of AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research note on Friday, September 12th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Bank of America lifted their price target on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Wall Street Zen upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Finally, UBS Group raised their target price on shares of AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average target price of $240.14.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.